Indications
treatment of HER2 (Human Epidermal Growth Factor Receptor 2)-positive metastatic breast cancer
Composition
- Active substance
- trastuzumab duocarmazine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Jivadco
- Active substance
- trastuzumab duocarmazine
- Marketing authorisation holder
- medac Gesellschaft für klinische Spezialpräparate mbH
- Status
- Application withdrawn
- EMA product number
- EMEA/H/C/005654
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- No
- Patient safety information
- No